Page 4 - Radioligand Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Radioligand therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Radioligand Therapy Today - Breaking & Trending Today

Curasight A/S reports positive preclinical results with uTREAT[®] in lung cancer (NSCLC)

Preclinical studies show uTREAT® effective in treating non-small cell lung cancer

Data follows recent announcement of positive preclinical results within glioblastoma and supports hypothesis. ....

Ulrich Krasilnikoff , Curasightas Curasight , Positron Emissions Tomography , Radioligand Therapy , Theranostic Platform ,

Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company

Ad hoc announcement pursuant to Art. 53 LR Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-offShares of Sandoz will be listed and commence. ....

United States , Samir Shah , Isabella Zinck , Parag Mahanti , Richard Jarvis , Julie Masow , Satoshi Sugimoto , Marlena Abdinoor , Novartis Adrs , Nicole Zinsli Somm , Michael Meo , Sandoz Adrs , Sloan Simpson , Exchange Commission , Swiss Exchange , American Depositary Receipts , Vas Narasimhan , Gene Therapy , Radioligand Therapy , Operating Income ,

Novartis executes Sandoz Spin-off; To "fully" focus on innovative medicines

Novartis executes Sandoz Spin-off; To "fully" focus on innovative medicines
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Novartis Adrs , Sandoz Adrs , Swiss Exchange , American Depositary Receipts , Vas Narasimhan , Gene Therapy , Radioligand Therapy , Operating Income , Sandoz Spin Off ,

Lilly enters radiopharma space with $1.4B buyout of Point Biopharma

Indianapolis-based Eli Lilly and Co. agreed to acquire Point Biopharma Global Inc. for $12.50 per share in cash, or about $1.4 billion, in a deal that would bring the pharma company a pipeline of preclinical and clinical radioligand therapies for cancer. The purchase price is an 87% premium to Point’s closing stock price on Oct. 2, and a 68% premium to the 30-day volume-weighted average price. Shares (NASDAQ:PNT) of Point, also of Indianapolis, rose 84.9%, or $5.67, to close at $12.36 on Oct. 3. ....

Eli Lilly , Point Biopharma Global Inc , Indianapolis Based Eli Lilly , Point Biopharma Global , Eli Lilly And Co , Point Biopharma Global Inc , Radioligand Therapy , Pnt 2002 , M Amp A , Radiopharma Therapies , Pnt 2003 ,

Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United States , New Jersey , Baja California , Marlena Abdinoor , Jeff Legos , Parag Mahanti , Richard Jarvis , Satoshi Sugimoto , Isabella Zinck , Samir Shah , Sloan Simpson , Julie Masow , Nicole Zinsli Somm , Michael Meo , Global Head Of Oncology Development At Novartis , Exchange Commission , Elsevier Inc , Executive Vice President , Global Head , Oncology Development , Advanced Accelerator Applications , Radioligand Therapy , Patients With Grade , Accessed September , Clin Adv Hematol , Survival Outcomes ,